Overview
Pancreatic cancer is one of the most feared diagnoses in oncology — but outcomes vary dramatically depending on where and by whom a patient is treated. At the world's highest-volume pancreatic cancer center, a pioneering full life-cycle management system has achieved a 5-year survival rate of 21.2% — more than four times the global average of 5% — representing one of the most significant advances in pancreatic cancer outcomes anywhere in the world.
China Medical Concierge Shanghai (CMCS) connects international patients with this center and its leading specialists, providing end-to-end support from remote consultation through to post-treatment follow-up.
Understanding Pancreatic Cancer
What Is Pancreatic Cancer?
Pancreatic cancer develops in the tissues of the pancreas and is one of the most aggressive malignancies in oncology. The most common type — pancreatic ductal adenocarcinoma (PDAC) — accounts for approximately 90% of cases. The global 5-year survival rate is less than 12%, largely due to late diagnosis and the aggressive biology of the tumor. However, at specialist high-volume centers with comprehensive, individualized treatment systems, outcomes can be dramatically better.
Common Symptoms
- Painless jaundice (yellowing of skin and eyes) — often the first sign of pancreatic head cancer
- Upper abdominal or back pain
- Unexplained weight loss and loss of appetite
- New-onset or worsening diabetes
- Nausea and vomiting
- Fatigue
- Light-colored stools and dark urine
Risk Factors
- Age over 60
- Smoking
- Chronic pancreatitis
- Diabetes mellitus
- Obesity and sedentary lifestyle
- Family history of pancreatic cancer
- Hereditary syndromes (BRCA1/2, Lynch syndrome)
Diagnosis & Staging
- CT scan (pancreatic protocol) — gold standard for staging and resectability assessment
- MRI / MRCP — biliary and pancreatic duct assessment
- Endoscopic ultrasound (EUS) with FNA — tissue diagnosis and local staging
- PET-CT — selected cases for distant metastasis
- CA19-9 and CEA — tumor markers
- Molecular profiling — BRCA1/2, KRAS, MSI/MMR, NTRK for targeted therapy eligibility
- MDT resectability assessment — formal multidisciplinary classification as resectable, borderline resectable, locally advanced, or metastatic
Treatment: Full Life-Cycle Pancreatic Cancer Management
Surgery
Surgical resection remains the only potentially curative treatment for pancreatic cancer. Procedures include:
- Pancreaticoduodenectomy (Whipple procedure) — for pancreatic head tumors
- Distal pancreatectomy — for body and tail tumors
- Total pancreatectomy — for tumors involving the entire pancreas
- Vascular resection and reconstruction — for tumors involving the portal vein or superior mesenteric vein
Robotic Pancreatic Surgery
The da Vinci robotic surgical system offers significant advantages for pancreatic surgery, providing enhanced 3D visualization, greater instrument precision in confined spaces, and improved ability to perform complex reconstructions. Robotic pancreaticoduodenectomy and distal pancreatectomy are routinely performed at Ruijin Hospital's pancreatic center — one of the world's most experienced robotic pancreatic surgery programs.
Full Life-Cycle Management System
The defining innovation of Ruijin Hospital's pancreatic cancer center is its full life-cycle (whole-journey) management system — a comprehensive, coordinated approach that addresses every phase of the patient's cancer journey:
- Early detection and high-risk screening — identifying pancreatic cancer at its earliest, most treatable stage
- Precision surgical planning — individualized surgical approach based on tumor anatomy and patient factors
- Perioperative optimization — minimizing surgical risk and accelerating recovery
- Adjuvant and systemic therapy — evidence-based chemotherapy and targeted therapy after surgery
- Long-term surveillance and follow-up — systematic monitoring for recurrence and management of late effects
- Palliative and supportive care — quality of life management for patients with advanced disease
This systematic, whole-journey approach — rather than treating surgery as an isolated event — is the key driver of the center's landmark survival outcomes.
Neoadjuvant & Conversion Therapy
For borderline resectable or locally advanced pancreatic cancer, neoadjuvant chemotherapy (FOLFIRINOX, gemcitabine + nab-paclitaxel) is used to downstage the tumor before surgery, converting borderline cases to resectable and in some locally advanced cases achieving surgical eligibility.
Systemic Therapy for Advanced Disease
- First-line: FOLFIRINOX or gemcitabine + nab-paclitaxel
- BRCA1/2-mutant: Olaparib maintenance
- MSI-H / dMMR: Pembrolizumab
- KRAS G12C-mutant: Emerging targeted options
Why Choose Shanghai for Pancreatic Cancer Treatment?
- World's highest surgical volume — Ruijin Hospital's pancreatic center has performed over 30,000 pancreatic cancer cases — the largest series in the world
- 21.2% five-year survival rate — more than four times the global average, achieved through the full life-cycle management system
- Robotic pancreatic surgery expertise — one of the world's most experienced robotic pancreatic surgery programs
- Multidisciplinary tumor boards — every complex case reviewed by surgery, medical oncology, radiation oncology, radiology, and pathology
- Cost-effective world-class care — significantly lower cost than equivalent treatment in the US, UK, or Singapore
Featured Specialist: Prof. Shen Baiyong — Ruijin Hospital, Shanghai Jiao Tong University
Prof. Shen Baiyong (沈柏用) is one of China's foremost pancreatic cancer surgeons and the founder of the world's largest comprehensive pancreatic cancer diagnosis and treatment center, based at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — one of China's most prestigious academic medical centers.
Prof. Shen serves as Vice Chairman of the General Surgery Subspecialty Committee of the Shanghai Medical Association — reflecting his leadership role in the broader surgical oncology community.
World Records in Pancreatic Cancer Care
- World's largest pancreatic cancer comprehensive diagnosis and treatment center — founded and built by Prof. Shen from the ground up
- Over 30,000 pancreatic cancer cases — the largest single-center series in the world
- World's highest surgical volume for pancreatic cancer — more pancreatic cancer operations than any other center globally
Landmark Survival Outcomes: 5% → 21.2%
Through the implementation of his full life-cycle pancreatic cancer management system, Prof. Shen's center has achieved a 5-year survival rate of 21.2% for pancreatic cancer patients — compared to the global average of approximately 5% at the time this system was developed. This represents a more than fourfold improvement in survival and places Ruijin Hospital's pancreatic cancer outcomes at the global leading level.
Robotic Surgery Pioneer
Prof. Shen is a pioneer of robotic pancreatic surgery in China, with extensive experience in da Vinci robotic pancreaticoduodenectomy and distal pancreatectomy. Robotic assistance provides enhanced precision for the complex dissection and reconstruction required in pancreatic surgery, with benefits including reduced blood loss, lower complication rates, and faster recovery.
Clinical Expertise
- Robotic and laparoscopic pancreatic surgery — Whipple procedure, distal pancreatectomy, total pancreatectomy
- Complex vascular resection and reconstruction — for locally advanced tumors involving major vessels
- Full life-cycle pancreatic cancer management — comprehensive, coordinated care from early detection through to survivorship
- Neoadjuvant and conversion therapy — for borderline resectable and locally advanced disease
- Multidisciplinary pancreatic cancer management — leading national MDT protocols
For international patients, Prof. Shen's team offers remote pre-consultation review of CT scans, MRI, CA19-9 levels, and pathology reports, enabling a precise resectability assessment and individualized treatment plan to be developed before arrival in Shanghai.
How CMCS Supports Your Journey
CMCS is not a hospital — we are your dedicated medical concierge, providing a trusted bridge between international patients and Shanghai's finest cancer specialists.
Our services include:
- ✅ Direct appointment coordination with Prof. Shen Baiyong and the Ruijin Hospital pancreatic cancer team
- ✅ CT scan, MRI, and pathology translation and remote resectability assessment
- ✅ Second opinion facilitation — especially for patients told their pancreatic cancer is inoperable
- ✅ Hospital admission and surgical scheduling support
- ✅ Accommodation and logistics coordination in Shanghai
- ✅ Post-treatment follow-up and remote check-in support
Contact CMCS
If you or a loved one has been diagnosed with pancreatic cancer and would like to explore treatment options in Shanghai, our team is ready to help.
📧 Email: contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 Website: www.medicalsh.com
CMCS — China Medical Concierge Shanghai. Connecting international patients with Shanghai's finest specialists.
0 則留言